There is no established, clinically validated human dose for BPC 157. Nearly all dosing data comes from rat and mouse studies, and only three small pilot studies have examined the peptide in people at all. One preclinical safety evaluation proposed roughly 200 micrograms per person per day as a starting point for clinical trials, but that figure has not been tested in large-scale human research. The gap between what animal experiments show and what anyone can confidently recommend for a person remains wide, and understanding why requires a closer look at what the studies actually used.
What the Animal Studies Actually Used
The vast majority of BPC 157 research has been conducted in rats, and the doses used are remarkably consistent across dozens of studies spanning tendons, ligaments, muscles, the gut, and the brain. Two dose tiers appear again and again: 10 micrograms per kilogram of body weight and 10 nanograms per kilogram. In a study on transected rat Achilles tendons, for instance, animals received 10 micrograms, 10 nanograms, or even 10 picograms per kilogram, injected into the abdomen once daily starting 30 minutes after surgery.1PubMed. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth Ligament repair studies used the same 10 microgram and 10 nanogram per kilogram range, delivered by injection, by topical cream, or dissolved in drinking water.2PubMed. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat Colitis models, brain ischemia experiments, and periodontitis studies all gravitated to the same dose window.3PubMed Central. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats
What stands out is that both the microgram and nanogram doses frequently produced measurable results. In the Achilles tendon study, the full improvement in biomechanical strength, functional recovery, and tissue quality showed up across the dose range, not only at the highest level. That pattern recurs in muscle crush injury research, where BPC 157 reduced hematoma, edema, and post-injury contracture while improving enzyme markers of damage.4PubMed. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat Whether this dose-response relationship would hold in humans is anyone’s guess, but in rats, the peptide appears to be active at doses spanning several orders of magnitude.
The Closest Thing to a Recommended Human Dose
In 2020, a preclinical safety evaluation performed acute and repeated-dose toxicity testing in rats and proposed a human clinical trial dose of 200 micrograms per person per day, equivalent to roughly 3.3 micrograms per kilogram per day for a 60-kilogram person. The proposed route was intramuscular injection over a seven-day course.5Regulatory Toxicology and Pharmacology. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds That same study found no deaths in rats given a single dose of 20 milligrams per kilogram, a dose roughly 6,000 times higher than the proposed human equivalent, which gave the researchers enough of a safety margin to feel comfortable recommending the lower figure for first-in-human testing.
This 200-microgram recommendation is the most concrete figure in the literature, and it gets repeated constantly in online peptide communities. But a proposed starting dose for a clinical trial is not the same thing as a proven effective dose for any condition. It was calculated from the rat pharmacology data using standard scaling methods, not from evidence that 200 micrograms does anything specific in people. The three small pilot human studies that do exist, examining knee pain, interstitial cystitis, and intravenous safety, have not generated the kind of dose-response data that would let anyone say with confidence what amount works for a given purpose.6Current Reviews in Musculoskeletal Medicine. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
Routes of Administration and Why They Matter for Dosing
BPC 157 has been tested in animals through several routes, and the effective dose changes depending on how it gets into the body. The most common route in published research is intraperitoneal injection, which delivers the peptide directly into the abdominal cavity. This is standard in rodent pharmacology but not something people do to themselves. Subcutaneous injection, the route most commonly discussed in online biohacking circles, has some overlap with intraperitoneal delivery in terms of absorption, but the two are not identical.
Oral administration is where things get more interesting, because BPC 157 is unusually stable for a peptide. Most peptides get chewed up by stomach acid and digestive enzymes within minutes, but BPC 157 was originally isolated from gastric juice and retains its activity in that environment.7PubMed. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease In the ligament healing study, rats given BPC 157 dissolved in drinking water at 0.16 micrograms per milliliter, consuming about 12 milliliters per day, showed the same pattern of functional and biomechanical improvement as rats getting injections.8PubMed. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat Colitis experiments also used this oral route with similar results.9Journal of Physiology and Pharmacology. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability
Topical application has been tested as well. In the ligament study, a thin layer of cream containing 1 microgram of BPC 157 per gram of neutral cream, applied directly over the injury site, also produced healing improvements. A separate study on alkali-burn wounds found that BPC 157 promoted cell proliferation, migration, and new blood vessel formation when applied to damaged tissue.10PubMed Central. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro A narrative review confirmed that BPC 157 can be administered orally, topically, or by injection, demonstrating healing potential across each route.11PubMed Central. Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review
The practical implication is that route and dose are tied together. Online vendors typically sell BPC 157 in vials containing 5 milligrams of lyophilized powder meant to be reconstituted for injection, or in capsule form for oral use. The oral doses circulating online tend to be higher than injection doses, on the logic that oral bioavailability is lower even for a stable peptide. Whether that logic is correct in practice has not been studied in humans.
Why Translating Rat Doses to Humans Is Not Straightforward
A common mistake is to take a rat dose in micrograms per kilogram and simply multiply by a human’s weight. A rat weighing 250 grams and a person weighing 70 kilograms do not metabolize drugs proportionally to their mass. Smaller animals have higher metabolic rates per unit of body weight, so they generally need proportionally higher doses to achieve the same blood levels. The standard method for converting between species accounts for differences in body surface area, not just weight.12PubMed Central. A simple practice guide for dose conversion between animals and human
Using that surface-area conversion, a 10-microgram-per-kilogram rat dose translates to roughly 1.6 micrograms per kilogram in a human. For someone weighing about 70 kilograms, that works out to around 112 micrograms. The 200-microgram-per-day figure from the safety study sits in the same general neighborhood, which is consistent: it was derived from the same type of scaling. But allometric scaling gives you an estimated equivalent exposure, not a guaranteed equivalent effect. BPC 157 may behave differently in human tissue, may distribute differently through a much larger body, and may interact with human physiology in ways that rat models cannot predict. Scaling is the starting line, not the finish.
What Happens at High Doses
The preclinical safety data is more reassuring than you might expect for an unregulated peptide. In the single-dose toxicity study, rats tolerated 20 milligrams per kilogram without any deaths, which is thousands of times higher than the doses used in the healing experiments.13Regulatory Toxicology and Pharmacology. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds The researchers also ran repeated-dose toxicity protocols, which are designed to catch problems that emerge only after prolonged exposure. The wide gap between the active dose range and the dose that caused visible toxicity is what gave the authors confidence to propose a clinical trial dose.
Rat cardiac experiments add an interesting wrinkle. BPC 157 counteracted hyperkalemia-induced arrhythmias and the systemic effects of succinylcholine at the same 10-microgram-per-kilogram dose used elsewhere in the literature.14PubMed. BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias The peptide did not just fail to cause cardiac harm; it appeared to protect against it. Still, these are rat experiments. The absence of toxicity in rodents does not guarantee the absence of toxicity in humans, particularly when the human data amounts to three small pilot studies.
How BPC 157 Works and Why the Mechanism Complicates Dosing
The dosing question would be simpler if BPC 157 had one clear target in the body. It does not. The peptide appears to work through several overlapping pathways, and which pathway matters most depends on what tissue you are looking at. In blood vessels, BPC 157 triggers nitric oxide production through the inner lining of the vessel wall, causing relaxation and improved blood flow in a concentration-dependent way.15PubMed Central. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway In tendons, the peptide increases the migration of fibroblasts, the cells responsible for laying down new connective tissue, also in a dose-dependent pattern.16PubMed. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
New blood vessel formation, or angiogenesis, is another consistent finding. BPC 157 increased vessel density both in living tissue and in lab models, and it accelerated the return of blood flow in ischemic muscle.17PubMed. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation The practical question this raises for dosing is whether you need different amounts of the peptide to drive angiogenesis versus tendon repair versus gut healing. In rats, the same 10 microgram per kilogram dose produces effects across many tissue types. But the optimal dose for one process in the human body may not be the optimal dose for another, and no one has teased those apart yet.
The nitric oxide connection also raises a consideration that rarely gets discussed in peptide forums. BPC 157’s interaction with the nitric oxide system is bidirectional: it modulates the effects of both nitric oxide promoters and nitric oxide inhibitors.18Current Pharmaceutical Design. Stable Gastric Pentadecapeptide BPC 157-NO-system Relation If you are already taking something that affects nitric oxide levels, like certain blood pressure medications or pre-workout supplements with arginine or citrulline, the interaction is at least theoretically relevant. No one has studied these combinations in humans.
Organ Protection and Anti-Inflammatory Doses
Some of the most compelling animal data involves BPC 157’s ability to protect organs against drug-induced damage. Rats given diclofenac, a common anti-inflammatory drug that causes gastrointestinal ulcers, liver injury, and even brain lesions at high doses, showed marked reversal of all three types of damage when treated with BPC 157.19Life Sciences. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: Diclofenac-induced gastrointestinal, liver, and encephalopathy lesions A similar study using celecoxib found that BPC 157 completely eliminated the liver damage at both 24 and 48 hours.20PubMed Central. Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME These organ-protection experiments used the standard 10 microgram and 10 nanogram per kilogram dose tiers.
This is relevant to the dosing discussion because many people interested in BPC 157 are using it alongside other medications, particularly anti-inflammatory drugs for joint pain or athletic injuries. The idea that it might buffer against side effects of those drugs is tantalizing, but it is still a rat finding, and combining unregulated peptides with prescription drugs without medical guidance is genuinely risky territory.
Brain and Nervous System Effects
BPC 157 has also been studied for neuroprotection. In a rat stroke model where blood flow to the brain was cut off for 20 minutes and then restored, applying BPC 157 at 10 micrograms per kilogram during reperfusion prevented both early and delayed brain damage. Treated rats recovered their performance on memory, balance, and motor tests.21PubMed Central. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats A broader review of BPC 157’s effects on the central nervous system noted that these neuroprotective benefits extended to other types of brain injuries as well.22PubMed Central. Pentadecapeptide BPC 157 and the central nervous system
The neuroprotection research also touches on neurotransmitter systems. BPC 157 modulates serotonin and dopamine activity in specific brain regions and has shown beneficial effects on behavioral disturbances linked to damaged or overstimulated neurotransmitter pathways.23Current Neuropharmacology. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications This is the kind of finding that makes researchers excited and should make self-experimenters cautious: a compound that alters dopamine and serotonin dynamics is not something to dose casually alongside antidepressants or stimulants.
The Regulatory Vacuum
Despite its growing popularity, particularly among athletes and fitness enthusiasts, BPC 157 exists in a regulatory gray zone. It is widely available from peptide suppliers online, but it is not approved as a drug or dietary supplement by any major regulatory agency. The compound is sold for “research purposes only” in most jurisdictions, a label that technically means it is not intended for human consumption, even though everyone involved knows what buyers are doing with it.
A recent narrative review emphasized the disconnect between the peptide’s popularity and its evidence base: only three pilot studies have examined BPC 157 in humans, covering knee pain, interstitial cystitis, and basic safety and pharmacokinetics.24Current Reviews in Musculoskeletal Medicine. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing That is an extraordinarily thin base for a compound thousands of people are injecting daily. The lack of regulation also means that product purity varies wildly. Without pharmaceutical-grade manufacturing oversight, there is no guarantee that what is in the vial matches what is on the label, and contamination or degradation is a real concern.
Purity and Reconstitution as Hidden Dosing Variables
Even if you settle on a target dose, the practical reality of obtaining and preparing BPC 157 introduces variables that most discussions ignore. The peptide typically arrives as a lyophilized powder that must be reconstituted with bacteriostatic water. The concentration of the resulting solution depends entirely on how much water you add. If a vial contains 5 milligrams and you add 2 milliliters of water, each 0.1 milliliter drawn into a syringe contains 250 micrograms. Add 2.5 milliliters instead, and the same 0.1 milliliter pull delivers 200 micrograms. Small measurement errors in reconstitution cascade into meaningful dosing errors, especially at the microgram scale.
Purity is the other unknown. Third-party testing by independent labs has found that peptide products from online sources vary in actual content, sometimes containing substantially less active peptide than claimed, sometimes containing degradation products. For a compound where the difference between the low and high end of the effective dose range in animal studies spans three orders of magnitude, getting the purity wrong might still land you in a range where something happens. But you would not know what you are actually taking, and that uncertainty compounds every other uncertainty in the dosing picture.
Musculoskeletal Healing and the “Spot Injection” Question
A common question among people using BPC 157 for injury recovery is whether injecting near the site of an injury works better than injecting elsewhere in the body. The animal data offers some indirect guidance. In the ligament study, local application as a cream, intraperitoneal injection, and oral dosing all produced improvements, though the study was not designed to compare relative effectiveness across routes head to head.25PubMed. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat The muscle healing literature similarly shows benefits from both systemic and local administration.26PubMed. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
The in vitro evidence adds some context. Tendon fibroblast migration increased in a dose-dependent manner in cell culture experiments, suggesting that higher local concentrations of BPC 157 at the injury site drive more robust cellular responses.27PubMed. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration That is the kind of finding that makes local injection intuitively appealing: you put the peptide where you want it to work. But a rat’s knee is a vastly different pharmacokinetic environment than a human’s, and the tissue distribution of a subcutaneous injection near a human tendon has not been mapped for this peptide. The honest answer is that both local and systemic administration have shown effects in animals, and no one has rigorously compared them in people.
Why Oral BPC 157 Gets a Different Conversation
Oral BPC 157, usually sold in capsule form, appeals to people who dislike needles or who are primarily interested in gut-related benefits. Given that the peptide was originally characterized in gastric juice, using it orally has a certain logic: it is returning to its natural environment. The stability data supports this, and rat studies confirm oral activity for both gut conditions and systemic effects like ligament healing.28PubMed. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease
The doses in the oral rat studies were lower than you might expect. At 0.16 micrograms per milliliter in drinking water consumed at about 12 milliliters per day, rats were getting roughly 1.9 micrograms per day total. For a 250-gram rat, that works out to about 7.7 micrograms per kilogram per day, which is in the same ballpark as the injection studies. Online oral doses for humans, however, tend to range from 250 to 500 micrograms per day in capsule form. Whether those capsule doses deliver enough intact peptide past the stomach and into circulation to produce systemic effects is an open question. For purely gut-related purposes, the peptide would not need to survive beyond the gastrointestinal tract, which may be why some users report digestive benefits from oral dosing even when they notice nothing for joint or muscle issues.
One clinical trial context is worth noting: BPC 157 reached early clinical testing for inflammatory bowel disease in humans, with the peptide given orally under the designation PL-10.29PubMed. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease The details of those trials remain sparse in published literature, but the fact that the oral route was chosen for a clinical-stage program suggests the developers believed oral delivery was viable in humans.
Joint Injections and Emerging Clinical Interest
The injection of BPC 157 directly into joints is a newer area of interest, particularly for knee pain. A clinical report on intra-articular injection for multiple types of knee pain suggested that the peptide has potential to repair tears, build cartilage, and reduce the need for surgery, with the authors arguing it offers advantages over steroid injections by addressing the underlying tissue damage rather than just suppressing inflammation.30PubMed. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain This is a promising direction, but the evidence remains preliminary. Intra-articular dosing is a medical procedure with its own set of risks, including infection, and should not be attempted outside of a clinical setting regardless of the peptide involved.
Periodontal research adds another local-use data point. In a rat model of gum disease, daily treatment with BPC 157 for 12 days reduced inflammation and significantly decreased alveolar bone loss compared to controls.31Academia.edu. Antiinflammatory effect of BPC 157 on experimental periodontitis in rats The peptide’s anti-inflammatory effects in the oral cavity hint at future dental applications, though this work remains squarely in the preclinical stage. For now, it serves mainly to illustrate how broadly BPC 157’s effects have been explored across tissue types, and how far the clinical evidence trails behind the mechanistic rationale.